GlassScriptPhysician profile
Loretta M Hoerman
NPI 1598764995
$610.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $39.34.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $129.37 | 2021 | |
| Abbvie INC. | $125.15 | 2021 | |
| Csl Behring | $57.01 | 2021-2022 | |
| Lilly USA, LLC | $45.45 | 2021 | |
| Genzyme Corporation | $43.09 | 2021 | |
| Emmaus Medical, INC. | $37.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.24 | 2021 | |
| Glaxosmithkline, LLC. | $27.87 | 2021-2022 | |
| Amgen INC. | $27.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.21 | 2021 | |
| Stryker Corporation | $20.14 | 2021 | |
| Amarin Pharma, INC. | $19.04 | 2021 | |
| Astellas Pharma US INC | $18.25 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loretta Hoerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.